- Home
- LBGJ vs ENLV Comparison
LBGJ vs ENLV Comparison
Compare LBGJ & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBGJ
- ENLV
- Stock Information
- Founded
- LBGJ 2007
- ENLV 2005
- Country
- LBGJ China
- ENLV Israel
- Employees
- LBGJ N/A
- ENLV N/A
- Industry
- LBGJ
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- LBGJ
- ENLV Health Care
- Exchange
- LBGJ NYSE
- ENLV Nasdaq
- Market Cap
- LBGJ 24.7M
- ENLV 23.7M
- IPO Year
- LBGJ 2024
- ENLV 1995
- Fundamental
- Price
- LBGJ $1.60
- ENLV $0.97
- Analyst Decision
- LBGJ
- ENLV Strong Buy
- Analyst Count
- LBGJ 0
- ENLV 2
- Target Price
- LBGJ N/A
- ENLV $10.00
- AVG Volume (30 Days)
- LBGJ 71.0K
- ENLV 46.3K
- Earning Date
- LBGJ 06-17-2025
- ENLV 05-30-2025
- Dividend Yield
- LBGJ N/A
- ENLV N/A
- EPS Growth
- LBGJ N/A
- ENLV N/A
- EPS
- LBGJ N/A
- ENLV N/A
- Revenue
- LBGJ $10,794,015.00
- ENLV N/A
- Revenue This Year
- LBGJ N/A
- ENLV N/A
- Revenue Next Year
- LBGJ N/A
- ENLV N/A
- P/E Ratio
- LBGJ N/A
- ENLV N/A
- Revenue Growth
- LBGJ N/A
- ENLV N/A
- 52 Week Low
- LBGJ $1.02
- ENLV $0.81
- 52 Week High
- LBGJ $5.50
- ENLV $1.76
- Technical
- Relative Strength Index (RSI)
- LBGJ N/A
- ENLV 49.07
- Support Level
- LBGJ N/A
- ENLV $0.93
- Resistance Level
- LBGJ N/A
- ENLV $0.98
- Average True Range (ATR)
- LBGJ 0.00
- ENLV 0.05
- MACD
- LBGJ 0.00
- ENLV -0.00
- Stochastic Oscillator
- LBGJ 0.00
- ENLV 43.09
About LBGJ LI BANG INTERNATIONAL CORPORATION I
Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.